So­sei Hep­tares to take back GPCR ag­o­nist af­ter GSK changes course

So­sei Hep­tares says it will con­tin­ue to de­vel­op its ear­ly-stage oral GPR35 ag­o­nist af­ter GSK gave the drug back fol­low­ing a de­ci­sion to stop its own work on the can­di­date.

So­sei Hep­tares first li­censed the can­di­date to GSK in 2020 and both com­pa­nies have since worked on pre­clin­i­cal de­vel­op­ment. But talks have now be­gun to re­turn the drug ful­ly to So­sei af­ter changes to GSK’s im­munol­o­gy re­search strat­e­gy and lead­er­ship. The com­pa­ny added that the trans­fer of the li­cense had noth­ing to do with pre­clin­i­cal da­ta from the can­di­date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER